NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Updated: May 25, 2022
NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
Sponsor
ClinicalTrials.gov Identifier: NCT04354246
Official Title: A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies
First Posted : April 21, 2020
Click here to see details on ClinicalTrials.gov
Drug: Dose escalation: COM902 monotherapy.
Combination Product: Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)
Drug: Cohort expansion: COM902 (RDFE) monotherapy.
Drug: Cohort expansion: COM902 in combination with COM701 (both at the RDFE).
Anti-TIGIT Monoclonal Antibody COM902 (Code C174037)
Anti-TIGIT Monoclonal Antibody COM902
COM 902
COM-902
COM902
Locations
United States, Michigan
United States, Ohio
United States, Tennessee
United States, Texas